A common antidepressant may ease long COVID's crushing fatigue, trial finds

For many people living with long COVID, fatigue is not simply tiredness, it is a persistent, often disabling exhaustion that can make ordinary tasks like showering, cooking or holding a conversation feel physically overwhelming. Despite years of research into the post-viral condition, doctors have had strikingly few treatments to offer for this specific symptom. A new randomized clinical trial suggests one may already be sitting in pharmacies: fluvoxamine, an antidepressant that has been available for decades.

The trial enrolled 399 adults diagnosed with long COVID and randomly assigned them to receive either fluvoxamine or a placebo over a defined treatment period, a design considered the gold standard for establishing whether a treatment effect is real rather than coincidental. Researchers tracked participants' fatigue levels and broader quality-of-life measures throughout the study using standardized assessment tools.

Participants who received fluvoxamine reported significantly greater reductions in fatigue than those who received the placebo, along with measurable improvements in overall quality of life. The researchers described the results as one of the first instances of a medication showing a clear, statistically meaningful benefit specifically for long COVID fatigue, a symptom that has proven notoriously difficult to treat.

Fluvoxamine belongs to a class of medications called selective serotonin reuptake inhibitors, commonly prescribed for depression and obsessive-compulsive disorder. It first drew interest as a potential COVID-related treatment earlier in the pandemic, when some researchers proposed that its anti-inflammatory and immune-modulating properties, separate from its effects on mood, might help dampen the excessive inflammatory response linked to severe illness and, potentially, to lingering post-viral symptoms.

The exact mechanism by which fluvoxamine might ease long COVID fatigue remains unclear, and the researchers were careful to note that the trial was not designed to explain why the effect occurs, only to measure whether it does. Leading theories in the broader long COVID research field point to persistent low-grade inflammation, disrupted serotonin signaling, and lingering immune system dysregulation as possible contributors to prolonged fatigue, any of which fluvoxamine could plausibly influence.

What makes the finding notable to clinicians is not just the result itself but the drug's profile. Fluvoxamine is inexpensive, has a long safety record from decades of use for depression and anxiety disorders, and is already widely available, meaning that if the finding holds up in further research, it could be adopted relatively quickly compared with a novel therapy that would need to go through the full drug development and approval pipeline.

Long COVID has affected millions of people worldwide since the pandemic began, with fatigue consistently ranking among the most commonly reported and most disabling symptoms in patient surveys, alongside brain fog, post-exertional malaise and sleep disturbance. Many patients have described years of consultations without a treatment that meaningfully addressed their fatigue, relying instead on pacing strategies to manage limited energy.

The researchers cautioned that a single trial, however well designed, is not sufficient to establish fluvoxamine as a standard treatment for long COVID fatigue, and called for larger, independent studies to confirm the effect, determine optimal dosing, and identify which patients are most likely to benefit. They also noted that fluvoxamine, like other SSRIs, carries known side effects and interactions that would need to be weighed against its potential benefit on a case-by-case basis.

Long COVID researchers not involved in the trial described the results as a promising, if preliminary, signal in a field that has seen relatively few positive treatment findings after years of study. Patient advocacy groups have repeatedly called for faster, better-funded trials of existing, repurposable medications, arguing that patients living with disabling symptoms cannot wait for treatments developed entirely from scratch.

For now, doctors say the finding does not amount to a blanket recommendation to prescribe fluvoxamine for every long COVID patient with fatigue, but it does give clinicians a concrete, evidence-based option to discuss with patients for whom other approaches have not helped, something that has been in short supply since the condition was first recognized.